According to Zacks, “Novadaq Technologies Inc. develops, manufactures and markets real-time fluorescence imaging products for use in the operating room and other clinical settings. The company’s key markets include plastic reconstructive, gastrointestinal, cardiac and general surgery. It provides SPY imaging systems which enables surgeons to the visualize blood flow in vessels, co-joined vessels and micro-vessels. Novadaq Technologies Inc. is headquartered in Mississauga, Canada. “
NVDQ has been the subject of several other research reports. Canaccord Genuity reaffirmed a buy rating and issued a $15.00 price objective on shares of Novadaq Technologies in a research report on Monday, August 29th. Feltl & Co. raised shares of Novadaq Technologies from a buy rating to a strong-buy rating in a research report on Thursday, July 28th. Northland Securities reissued an underperform rating and set a $7.00 price target on shares of Novadaq Technologies in a research report on Thursday, July 7th. Finally, Wedbush reissued a positive rating and set a $17.00 price target on shares of Novadaq Technologies in a research report on Tuesday, September 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and an average price target of $13.42.
Novadaq Technologies (NASDAQ:NVDQ) opened at 10.30 on Wednesday. The firm has a 50-day moving average of $11.59 and a 200 day moving average of $10.78. The firm’s market capitalization is $591.58 million. Novadaq Technologies has a 52 week low of $8.26 and a 52 week high of $14.36.
Novadaq Technologies (NASDAQ:NVDQ) last issued its quarterly earnings data on Wednesday, July 27th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.15. Novadaq Technologies had a negative net margin of 49.45% and a negative return on equity of 25.28%. The firm earned $20.12 million during the quarter, compared to analyst estimates of $19.97 million. During the same period last year, the business earned ($0.22) EPS. The firm’s revenue was up 33.5% compared to the same quarter last year. Analysts predict that Novadaq Technologies will post ($0.73) earnings per share for the current year.
Institutional investors have recently made changes to their positions in the company. Royce & Associates LP boosted its position in shares of Novadaq Technologies by 20.5% in the first quarter. Royce & Associates LP now owns 193,900 shares of the company’s stock valued at $2,150,000 after buying an additional 33,000 shares during the period. UBS Group AG boosted its position in shares of Novadaq Technologies by 2.5% in the first quarter. UBS Group AG now owns 97,800 shares of the company’s stock valued at $1,085,000 after buying an additional 2,425 shares during the period. Primecap Management Co. CA boosted its position in shares of Novadaq Technologies by 5.6% in the first quarter. Primecap Management Co. CA now owns 5,260,582 shares of the company’s stock valued at $58,340,000 after buying an additional 279,502 shares during the period. AXA boosted its position in shares of Novadaq Technologies by 36.3% in the first quarter. AXA now owns 1,089,491 shares of the company’s stock valued at $12,082,000 after buying an additional 290,276 shares during the period. Finally, Altrinsic Global Advisors LLC boosted its position in shares of Novadaq Technologies by 1.1% in the first quarter. Altrinsic Global Advisors LLC now owns 441,100 shares of the company’s stock valued at $4,892,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 88.63% of the company’s stock.
About Novadaq Technologies
Novadaq Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novadaq Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.